Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126865571 | 12686557 | 1 | I | 20160508 | 20160810 | 20160825 | 20160825 | EXP | CN-PFIZER INC-2016401515 | PFIZER | 66.00 | YR | F | Y | 0.00000 | 20160825 | OT | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126865571 | 12686557 | 1 | PS | LIPITOR | ATORVASTATIN CALCIUM | 1 | Oral | 20 MG, 1X/DAY | 560 | MG | Y | M91694 | 20702 | 20 | MG | FILM-COATED TABLET | QD | ||
| 126865571 | 12686557 | 2 | SS | LIPITOR | ATORVASTATIN CALCIUM | 1 | 560 | MG | Y | 20702 | FILM-COATED TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126865571 | 12686557 | 1 | Arteriosclerosis |
| 126865571 | 12686557 | 2 | Lipids |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126865571 | 12686557 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126865571 | 12686557 | Blood creatine phosphokinase increased | |
| 126865571 | 12686557 | Muscle injury | |
| 126865571 | 12686557 | Myalgia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126865571 | 12686557 | 1 | 20160411 | 20160509 | 0 |